| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the ...
MOLN: 11% | Molecular Partners shares are trading higher after the company announced the debut of their lead Raido-DARPin thera...
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech com...
The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023
Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yis...
CMND: 60% | Clearmind Medicine shares are trading higher after the company signed an exclusive patent licensing agreement with ...
